Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Viatris Inc. (VTRS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
9.86+0.05 (+0.51%)
At close: 04:00PM EDT
10.00 +0.14 (+1.42%)
After hours: 07:55PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close9.81
Open9.84
Bid9.84 x 2900
Ask10.00 x 4000
Day's Range9.84 - 10.02
52 Week Range8.46 - 12.40
Volume6,051,996
Avg. Volume8,391,671
Market Cap11.827B
Beta (5Y Monthly)1.18
PE Ratio (TTM)6.44
EPS (TTM)1.53
Earnings DateNov 06, 2023 - Nov 10, 2023
Forward Dividend & Yield0.48 (4.89%)
Ex-Dividend DateAug 23, 2023
1y Target Est14.78
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Near Fair Value
4% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for VTRS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Viatris Inc.
    Analyst Report: Viatris Inc.Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
    Rating
    Fair Value
    Economic Moat
    23 days agoMorningstar
View more
Advertisement
Advertisement